Although several different clinical trial designs have been employed, 2,3,4 the most common and straightforward methodology to test a promising disease modifying therapy is to assess its ability to slow progression of clinical signs and symptoms versus placebo over time in patients with early PD while they are not receiving symptomatic PD medications (e.g., levodopa, dopamine agonists, MAO-B inhibitors)
Among these, only four studies provided comparable dichotomous data on AMS incidence, which were included in the quantitative meta-analysis
Alternative medication formats Injectable GLP-1 medications are not the only option
Sin embargo, no son tratamientos estticos ni deben utilizarse sin supervisin profesional
Success hinges on understanding how these medications work and actively partnering with them through thoughtful lifestyle choices